Why adults at risk for Huntington's choose not to learn if they inherited deadly gene

May 16, 2019

WASHINGTON (May 16, 2019)-- As many as 90 percent of individuals who have a parent with Huntington's disease (HD) choose not to take a gene test that reveals if they will also develop the fatal disorder -- and a new study details the reasons why.

Understanding the "why" matters as new clinical trials testing therapies for people who haven't yet developed symptoms of Huntington disease requires participants to be tested for the HD gene to be included in the trials.

The study, published today in Clinical Genetics, also suggests that individuals who have chosen not to be tested can benefit from supportive counseling, which is not usually offered.

"Health care providers really need to help individuals at risk for Huntington's disease think through their decision whether or not to participate in a clinical trial that requires testing," says the study's lead investigator, Karen E. Anderson, MD, an associate professor of psychiatry & neurology at Georgetown University Medical Center. "For someone who has not wanted genetic testing for many years, we may be leading people to do a test that has not been and still may not be in their personal interest."

She says, "For those who want testing and are ready to cope with the result, either positive or negative, it is our duty to help them get this information so they can make decisions about future care, financial planning and, possibly, study participation. For those who are not ready to be tested, or never want testing, we need also to support their choices," says Anderson, who is also director of Huntington's Disease Care, Education & Research Center, a joint program of Georgetown University and MedStar Georgetown Hospital.

Huntington's disease is caused by an inherited defect in a single gene. Inheritance is autosomal dominant: only one copy of a mutated HD gene is needed to pass on the disorder, thus the chance of inheritance is 50 percent. (A person inherits two copies of every gene, one from each parent. A parent with a defective gene can pass on either a mutant or healthy HD gene.)

The disease produces progressive degeneration of nerve cells in the brain, which affects the ability to move and think, and often results in depression and other psychiatric disorders due to functional changes in the brain.

To date, there is no cure for the disease and no way to prevent its onset. It is always fatal. People who have the HD genetic mutation expansion will develop HD (unless they die of other causes before it develops). Anderson says there are effective treatments for the symptoms, and a "pipeline" of drugs that may alter the course of the disease are now in clinical testing. Among them are gene silencing techniques that may lower the level of abnormal protein that is produced by the HD gene.

The age at which a person with the HD genetic mutation develops the disorder depends on the number of times a coding mistake in the gene is repeated. Symptoms in adults can begin as early as age 20, or, more likely, in mid-life, (ages 30-50). Onset after age 80 has been reported. Once they begin, symptoms worsen over 10-25 years until death.

The HD gene that causes the disease was isolated in 1993 and a predictive gene test quickly followed. Studies have been conducted on why people choose to take the gene test, but only one large study has been done on why people don't -- the subject of the Clinical Genetics publication.

This study included 1001 potential HD mutation carriers who had chosen not to learn their HD status. These individuals agreed to participate in the Prospective Huntington At-Risk Observational Study (PHAROS), carried out between 1999 and 2008. Data from a subset of 733 of these subjects were used in the current report by Anderson and others.

The two primary reasons why participants did not want to know their risk was because they felt no effective cure or treatment exists and their inability to undo the knowledge they learned from the test.

"Our subjects were optimistic that a treatment to improve symptoms or postpone treatment would be developed with the next ten years, but they had less certainty about the prospect of preventing the disease," Anderson says.

"Back in 1993, when the genetic mutation causing HD was discovered, we anticipated that many people at risk would want to be tested, just to deal with the uncertainty, but that is not the case. Only about 10-15 percent of people who know they are at risk for HD have been tested since the test became available, and that percentage really hasn't changed much over time. This study shows there are important, relevant reasons why people don't want to be tested," she says.

As part of the PHAROS study, participants gave permission for gene analysis with the understanding that they would not be told the results.

Helping to understand why people chose not to test makes it easier for physicians and genetic counselors to broach the subject with individuals at risk, especially if they are considering a clinical trial, she says.

"We already know that clinicians have fewer conversations with people at risk for Huntington's who chose not to test, compared with people who do seek a test, who receive evaluation and supportive counseling prior to testing. Now we know factors people cite for why they don't want to know their status," says Anderson.

"This study shows us that, as new treatments develop that will require genetic testing for clinical trial participation, we should reassess attitudes about how people at risk for disease approach this life-altering choice. It tells us that we should understand, and respect, decisions not to have that testing," she says.

Currently there are about 30,000 Americans who are symptomatic, and more than 200,000 who are at risk of developing the disease, according to the Huntington's Disease Society of America.
-end-
This study was supported by research grant awards from the National Human Genome Research Institute (HG02449) and the National Institute of Neurological Disorders and Stroke of the National Institutes of Health), theCHDI (High Q) Foundation (New York, NY), the Huntington's Disease Society of America (New York, NY), the Hereditary Disease Foundation (Santa Monica, Calif), the Huntington Society of Canada (Kitchener, Ontario), and the Fox Family Foundation (New Jersey). Dr. Anderson's effort was also supported by the Griffin Foundation.

Study co-authors include senior researcher Ira Shoulson, MD, from Georgetown and the University of Rochester, Shirley Eberly, MS, David Oakes, PhD, and Elise Kayson, MS, from the University of Rochester, Karen S. Marder, MD, MPH, from Columbia University, and Anne Young, MD, PhD, from Harvard University.



About Georgetown University Medical Center


Georgetown University Medical Center (GUMC) is an internationally recognized academic medical center with a three-part mission of research, teaching and patient care (through MedStar Health). GUMC's mission is carried out with a strong emphasis on public service and a dedication to the Catholic, Jesuit principle of cura personalis -- or "care of the whole person." The Medical Center includes the School of Medicine and the School of Nursing & Health Studies, both nationally ranked; Georgetown Lombardi Comprehensive Cancer Center, designated as a comprehensive cancer center by the National Cancer Institute; and the Biomedical Graduate Research Organization, which accounts for the majority of externally funded research at GUMC including a Clinical and Translational Science Award from the National Institutes of Health. Connect with GUMC on Facebook (Facebook.com/GUMCUpdate), Twitter (@gumedcenter) and Instagram (@gumedcenter).

Georgetown University Medical Center

Related Clinical Trial Articles from Brightsurf:

Clinical trial investigates gabapentin for alcohol use disorder
This randomized clinical trial investigated if gabapentin, a drug often used to treat nerve pain, would be useful in the treatment of patients with alcohol use disorder (problem drinking that becomes severe) and a history of alcohol withdrawal symptoms.

Electrical stimulation helps treat constipation in clinical trial
Electrical stimulation benefited women with constipation in a recent clinical trial published in Alimentary Pharmacology & Therapeutics.

Treatment of migraine pain in randomized clinical trial
Adults experiencing a migraine of moderate or severe severity took the drug ubrogepant or placebo and reported if after two hours they were free of pain and of their most bothersome migraine-associated symptom in this randomized clinical trial.

First entirely digital clinical trial encourages physical activity
As little as a daily ping on your phone can boost physical activity, researchers from the Stanford University School of Medicine and their collaborators report in a new study.

HIV vaccine nears clinical trial following new findings
A promising vaccine that clears an HIV-like virus from monkeys is closer to human testing after a new, weakened version of the vaccine has been shown to provide similar protection as its original version.

Sickle cell drug showing promise in clinical trial
An investigational drug for the treatment of sickle cell disease is showing early promise in clinical trials for impacting biomarkers of the disease in patients, reported UConn School of Medicine researchers.

Meditation goes digital in new clinical trial
Scientists at UC San Francisco have developed a personalized digital meditation training program that significantly improved attention and memory in healthy young adults -- a group already at the peak of brain health -- in just six weeks.

Could blockchain ensure integrity of clinical trial data?
UC San Francisco researchers have created a proof-of-concept method for ensuring the integrity of clinical trials data with blockchain.

Eating crickets can be good for your gut, according to new clinical trial
A new clinical trial shows that consuming crickets can help support the growth of beneficial gut bacteria and that eating crickets is not only safe at high doses but may also reduce inflammation in the body.

Idera Pharmaceuticals presents clinical data from the ILLUMINATE-204 trial of the combination of tilsotolimod and ipilimumab for anti-PD-1 refractory metastatic melanoma at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting
Idera Pharmaceuticals Inc., a clinical-stage biopharmaceutical company developing toll-like receptor and RNA therapeutics for patients with rare cancers and rare diseases, announced results from the ongoing ILLUMINATE-204 trial investigating tilsotolimod, Idera's intratumorally-delivered Toll-like Receptor 9 agonist, in combination with ipilimumab (Yervoy®).

Read More: Clinical Trial News and Clinical Trial Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.